Clear Vision
For Life
Targeting Large Unmet Needs In Ophthalmology
We are working on a large unmet need affecting 10 million patients in North America only.
Targeting Fuchs’ Endothelial Corneal Dystrophy (FECD) as an initial indication, TelomEYE intends to bring a twice-a-day ophthalmic solution aiming to restore/preserve/treat vision loss of nearly 9 million Americans 1 million Canadians who do not have any approved product.
TelomEYE is using 2009 Nobel Prize Winning Technology to protect and vitalize corneal endothelial cells.
What is Fuchs' dystrophy?
The cornea is the windshield of the eye and must remain completely clear to maintain pristine vision.
Fuchs Corneal Dystrophy is a progressive disease in which the endothelial cells of both eyes prematurely degenerate, leading to severe vision.
Contact Us
Please contact us for more information
JLabs @ Toronto
661 University Avenue Suite 1300 M5G0B7